Cardiogen (20mg)

Cardiogen (20mg): A Short Bioregulator Peptide with Tissue-Specific Epigenetic Regulatory Activity in Cardiac Tissue — Investigated for Cardiomyocyte Gene Expression Modulation, Cardiovascular Support, and Age-Related Cardiac Function Research

"Bioregulator peptides (cytogens) represent a novel class of tissue-specific signaling molecules that penetrate cell and nuclear membranes, interact directly with DNA, and modulate gene expression in a tissue-specific manner — offering a fundamentally different mechanism of action from receptor-mediated peptide signaling."
— Khavinson VK, et al. Bulletin of Experimental Biology and Medicine. 2009;147(3):315-322.

Cardiogen is a short bioregulator peptide (cytogen) developed by the St. Petersburg Institute of Bioregulation and Gerontology under the direction of Professor Vladimir Khavinson, a pioneer in the field of peptide bioregulation and gerontology^[1]. Bioregulator peptides are a unique class of short peptides (typically 2-4 amino acids in length) that are distinguished from conventional receptor-mediated peptide signaling molecules by their ability to penetrate both cell membranes and nuclear membranes, interact directly with DNA in the cell nucleus, and modulate gene expression in a tissue-specific manner^[2]. Cardiogen is specifically designed to target cardiac tissue (cardiomyocytes), where it is believed to interact with DNA to modulate the expression of genes involved in cardiac function, cellular metabolism, oxidative stress response, and age-related cellular decline^[3].

The mechanism of action of Cardiogen — and bioregulator peptides in general — represents a paradigm distinct from conventional peptide pharmacology. Most therapeutic peptides (such as GHRH analogs, GHRPs, or insulin) act by binding to specific cell-surface receptors, triggering intracellular signaling cascades that produce cellular responses. Bioregulator peptides, by contrast, are believed to act through direct epigenetic regulation: their small size and specific amino acid composition allow them to cross the cell membrane and the nuclear membrane, enter the nucleus, and interact directly with DNA — potentially binding to specific gene promoter regions or interacting with chromatin structure to modulate gene expression^[4]. This tissue-specific gene regulatory activity is thought to underlie the observed effects of bioregulator peptides on cellular function, tissue homeostasis, and age-related decline in their target tissues^[5].

Key Research Findings and Proposed Mechanisms

1. Tissue-specific DNA interaction: Bioregulator peptides like Cardiogen are believed to interact directly with DNA in the nuclei of their target cells (cardiomyocytes), potentially binding to specific gene promoter regions to modulate gene expression. This tissue specificity is determined by the peptide's unique amino acid sequence and charge distribution^[1].
2. Cardiac gene expression modulation: Preclinical research suggests that Cardiogen may modulate the expression of genes involved in cardiac muscle contractility, energy metabolism, oxidative stress response, and cellular repair pathways in cardiomyocytes — potentially contributing to maintenance of cardiac function^[3].
3. Antioxidant and cytoprotective effects: Bioregulator peptides have been shown in preclinical studies to reduce oxidative stress markers, enhance antioxidant enzyme activity, and protect cells from oxidative damage — effects that may be particularly relevant in cardiac tissue, which has high metabolic activity and oxygen consumption^[6].
4. Age-related cardiac function research: Cardiogen is part of a broader family of bioregulator peptides developed by Professor Khavinson's group for research into age-related decline in various organ systems. Preclinical studies in animal models of aging have suggested that bioregulator peptides may help maintain tissue-specific cellular function and reduce age-related functional decline^[7].
5. Safety and tolerability profile: Bioregulator peptides are generally well-tolerated in preclinical studies, with minimal reported adverse effects. Their small size and peptide composition suggest rapid metabolism and clearance, and their mechanism of action (epigenetic gene regulation) is distinct from receptor-mediated signaling, potentially reducing the risk of receptor desensitization or downregulation^[8].
6. Synergistic potential with other peptides: Some research has investigated the potential synergistic effects of combining bioregulator peptides with conventional peptide signaling molecules or other bioregulator peptides. However, the specific combinations and optimal protocols remain areas of active investigation^[9].
7. Research use only: Cardiogen is available for laboratory research purposes only. It is not approved for human clinical use, and its effects in humans have not been fully established. All research with Cardiogen should be conducted in accordance with applicable institutional guidelines and regulatory requirements^[10].

References

1. Khavinson VK, et al. Peptide bioregulation of aging: results and prospects. Bulletin of Experimental Biology and Medicine. 2009;147(3):315-322. (Bioregulator peptide overview)
2. Khavinson VK, Linkova NS. Peptides and aging: a review. Current Pharmaceutical Design. 2011;17(33):3632-3639. (Peptide bioregulation mechanism)
3. Khavinson VK, et al. Cardiac peptide bioregulators: experimental and clinical studies. Bulletin of Experimental Biology and Medicine. 2012;153(1):32-37. (Cardiogen cardiac tissue research)
4. Khavinson VK, et al. Gene expression regulation by short peptides. Doklady Biochemistry and Biophysics. 2010;431:113-116. (DNA interaction mechanism)
5. Linkova NS, et al. The role of peptide bioregulators in maintaining cellular homeostasis. Advances in Gerontology. 2018;8(2):215-222. (Tissue homeostasis and gene regulation)
6. Khavinson VK, et al. Antioxidant properties of peptide bioregulators. Bulletin of Experimental Biology and Medicine. 2015;159(1):38-43. (Antioxidant effects of bioregulator peptides)
7. Anisimov VN, et al. Effects of peptide bioregulators on lifespan and aging in animal models. Current Pharmaceutical Design. 2010;16(33):3623-3631. (Age-related decline research)
8. Khavinson VK, et al. Safety and tolerability of peptide bioregulators: a review. Bulletin of Experimental Biology and Medicine. 2013;155(1):25-30. (Safety profile of bioregulator peptides)
9. Linkova NS, Khavinson VK. Synergistic effects of peptide combinations in bioregulation. Advances in Gerontology. 2020;10(1):45-52. (Combination research with bioregulator peptides)
10. Khavinson VK. Peptide bioregulators: from laboratory research to practical application. Herald of the Russian Academy of Sciences. 2016;86(3):245-253. (Research use and regulatory status)